Rare neuromuscular diseases (NMDs) encompass various disorders of the nervous system and skeletal muscles, and present intricate challenges in diagnosis, treatment, and research due to their low prevalence and often diverse multisystemic manifestations. Leveraging collected patient data for secondary use and analysis holds promise for advancing medical understanding in this field. However, a certain level of data quality is a prerequisite for the methods that can be used to analyze data.
View Article and Find Full Text PDFObjective: Unlocking the potential of routine medical data for clinical research requires the analysis of data from multiple healthcare institutions. However, according to German data protection regulations, data can often not leave the individual institutions and decentralized approaches are needed. Decentralized studies face challenges regarding coordination, technical infrastructure, interoperability and regulatory compliance.
View Article and Find Full Text PDFSince 72% of rare diseases are genetic in origin and mostly paediatrics, genetic newborn screening represents a diagnostic "window of opportunity". Therefore, many gNBS initiatives started in different European countries. Screen4Care is a research project, which resulted of a joint effort between the European Union Commission and the European Federation of Pharmaceutical Industries and Associations.
View Article and Find Full Text PDFBundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
November 2022
People with rare diseases (RDs) have particular potential to benefit from digitisation in the healthcare system. The National Action Alliance for People with Rare Diseases (NAMSE) has campaigned for SE to be specifically taken into account in the digitisation of the healthcare system in Germany. The topic was addressed within the Medical Informatics Initiative (MII) of the Federal Ministry of Education and Research (BMBF).
View Article and Find Full Text PDFBackground: The low number of patients suffering from any given rare diseases poses a difficult problem for medical research: With the exception of some specialized biobanks and disease registries, potential study participants' information are disjoint and distributed over many medical institutions. Whenever some of those facilities are in close proximity, a significant overlap of patients can reasonably be expected, further complicating statistical study feasibility assessments and data gathering. Due to the sensitive nature of medical records and identifying data, data transfer and joint computations are often forbidden by law or associated with prohibitive amounts of effort.
View Article and Find Full Text PDFStud Health Technol Inform
June 2020
The cryptographic method Secure Multi-Party Computation (SMPC) could facilitate data sharing between health institutions by making it possible to perform analyses on a "virtual data pool", providing an integrated view of data that is actually distributed - without any of the participants having to disclose their private data. One drawback of SMPC is that specific cryptographic protocols have to be developed for every type of analysis that is to be performed. Moreover, these protocols have to be optimized to provide acceptable execution times.
View Article and Find Full Text PDFBackground: Emerging machine learning technologies are beginning to transform medicine and healthcare and could also improve the diagnosis and treatment of rare diseases. Currently, there are no systematic reviews that investigate, from a general perspective, how machine learning is used in a rare disease context. This scoping review aims to address this gap and explores the use of machine learning in rare diseases, investigating, for example, in which rare diseases machine learning is applied, which types of algorithms and input data are used or which medical applications (e.
View Article and Find Full Text PDF